SynthesisJournal of cancer research and clinical oncology2019
Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population.
Synthesis in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer.International journal of medical sciences · 2021Pooled it
- Association of the Expression Level of miR-16 with Prognosis of Solid Cancer Patients: A Meta-Analysis and Bioinformatic Analysis.Disease markers · 2020Pooled it
- Prognostic and clinicopathological significance of long non-coding RNA UCA1 in colorectal cancer: Results from a meta-analysis.Medicine · 2019Pooled it
- In Silico Identification of circPIM1/miR-16-5p/miR-195-5p/PIM1 Feed-Forward Loop in Recurrent Grade 2 Meningioma.International journal of molecular sciences · 2025Article
- Review
- Identification and evaluation of a serum microRNA panel to diagnose colorectal cancer patients.International journal of cancer · 2025Article
- Plasma microRNA-15a/16-1-based machine learning for early detection of hepatitis B virus-related hepatocellular carcinoma.Liver research (Beijing, China) · 2024Article
- Differentially expressed microRNA in prognosis of gastric cancer with Lauren classification.Cancer biomarkers : section A of Disease markers · 2024Article
- Extracellular Vesicles' Genetic Cargo as Noninvasive Biomarkers in Cancer: A Pilot Study Using ExoGAG Technology.Biomedicines · 2023Article
- Altered miRNA Expression Profiles in the Serum of Beagle Dogs Experimentally Infected withAnimals : an open access journal from MDPI · 2023Article
- MicroRNAs miR-16 and miR-519 control meningioma cell proliferationFrontiers in oncology · 2023Article
- Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update.Cancers · 2022Review
- The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.Methods in molecular biology (Clifton, N.J.) · 2022Article
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling.Cell cycle (Georgetown, Tex.) · 2021Article
- MicroRNAs Related to Cognitive Impairment After Hearing Loss.Clinical and experimental otorhinolaryngology · 2021Article
- Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors.Cancers · 2020Article
- Local and Systemic Humoral Response to Autologous Lineage-Negative Cells Intrathecal Administration in ALS Patients.International journal of molecular sciences · 2020Article
- miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6.Cancer cell international · 2020Article
- Identification of miR-4644 as a suitable endogenous normalizer for circulating miRNA quantification in hepatocellular carcinoma.Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCancer is a serious public health problem worldwide, and difficulty in early diagnosis has been the chief obstacle to improve the prognosis of patients. Recently, microRNAs (miRNAs) were widely studied to be potential biomarkers for cancer detection. miR-16 is a prevalent but sophisticated one. In the current study, we aimed to assess the diagnostic value of serum miR-16 for cancer detection.
methodsA total of 1458 cancer patients, containing ten types of cancers, and 1457 non-cancer controls were recruited in this study. qRT-PCR was used for the amplification of miRNAs. In addition, a meta-analysis of reported studies was performed to confirm our findings systematically.
resultsConsequently, miR-16 was down-regulated in ESCC, GCA and GNCA patients compared with NCs (all P < 0.001), while up-regulated in PDAC patients (P = 0.001), LAC, LSCC and EEC patients (all P < 0.001). But no significant differences were observed in CRC, EOC and TC patients when compared to NCs (P = 0.747, 0.235 and 0.268, respectively). The areas under the receiver operating characteristic (ROC) curve of miR-16 in GCA, ESCC, LAC, LSCC, GNCA, PDAC and EEC were 0.881, 0.780, 0.757, 0.693, 0.602, 0.614 and 0.681, respectively. Results of meta-analysis showed that miR-16 achieved an overall pooled sensitivity of 0.72, specificity of 0.79, and AUC of 0.85, suggesting that miR-16 was a promising biomarker in cancer detection.
conclusionsWe provided a comprehensive view of the diagnostic value of serum miR-16 in cancer diagnosis, and confirmed that circulating miR-16 could play an important role in cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.